Profile data is unavailable for this security.
About the company
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Bayer and Syngenta in Agriculture and DSM and Adisseo in Animal Health & Nutrition..
- Revenue in DKK (TTM)22.73bn
- Net income in DKK2.11bn
- Incorporated2000
- Employees10.45k
- LocationNovozymes A/SKrogshoejvej 36BAGSVAERD 2880DenmarkDNK
- Phone+45 44460000
- Fax+45 44469999
- Websitehttps://www.novozymes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arkema SA | 70.82bn | 2.58bn | 42.67bn | 21.10k | 16.32 | 0.7789 | 5.01 | 0.6025 | 4.61 | 4.61 | 126.47 | 96.55 | 0.6703 | 5.51 | 6.76 | 453,213.00 | 2.63 | 5.99 | 3.18 | 7.23 | 20.45 | 21.46 | 3.92 | 7.59 | 1.54 | 8.88 | 0.3716 | 31.72 | -17.63 | 1.54 | -57.64 | -9.82 | 2.78 | 6.96 |
Croda International Plc | 14.59bn | 1.46bn | 43.76bn | 5.85k | 30.05 | 2.11 | 16.45 | 3.00 | 1.17 | 1.17 | 11.67 | 16.62 | 0.4577 | 2.36 | 4.53 | 278,451.80 | 4.60 | 10.80 | 5.11 | 12.51 | 43.86 | 46.41 | 10.05 | 18.64 | 1.67 | 10.59 | 0.2349 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
Yara International ASA | 98.57bn | 3.87bn | 52.04bn | 18.00k | 13.44 | 0.9605 | 4.63 | 0.5279 | 23.76 | 23.76 | 604.96 | 332.50 | 0.8712 | 3.49 | 8.34 | 8,561,082.00 | 3.45 | 5.30 | 4.44 | 6.97 | 27.23 | 26.69 | 3.96 | 5.60 | 0.9627 | 6.37 | 0.3699 | 94.60 | -35.44 | 3.60 | -98.27 | -21.30 | -2.76 | -8.10 |
Syensqo NV | -745.97bn | -745.97bn | 56.24bn | 13.05k | -- | 1.01 | -- | -- | -- | -- | -- | 70.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.08 | -- | 0.2239 | -- | -13.02 | -- | -79.68 | -- | -- | -- |
Evonik Industries AG | 113.11bn | 1.70bn | 60.43bn | 33.58k | 36.20 | 0.8984 | 6.26 | 0.5343 | 0.4803 | 0.4803 | 32.02 | 19.35 | 0.7514 | 4.22 | 8.64 | 453,859.80 | 1.21 | 2.01 | 1.54 | 2.42 | 25.25 | 25.47 | 1.61 | 2.90 | 0.7371 | 9.95 | 0.3168 | 130.72 | -17.42 | 2.85 | -186.27 | -- | -3.51 | 0.3454 |
Imcd NV | 33.87bn | 2.09bn | 60.85bn | 5.01k | 27.98 | 4.49 | 19.99 | 1.80 | 4.93 | 4.93 | 79.74 | 30.72 | 1.08 | 5.53 | 5.22 | 958,630.50 | 6.66 | 7.01 | 9.66 | 9.60 | 22.37 | 21.40 | 6.19 | 5.80 | 0.8846 | 5.67 | 0.5087 | 44.25 | -3.45 | 13.30 | -6.65 | 23.91 | 24.09 | 22.87 |
Brenntag SE | 120.78bn | 4.06bn | 64.00bn | 17.70k | 16.17 | 1.96 | 9.69 | 0.5299 | 3.67 | 3.67 | 109.07 | 30.28 | 1.49 | 8.20 | 6.72 | 914,269.60 | 5.10 | 6.40 | 7.30 | 9.02 | 24.66 | 23.03 | 3.41 | 4.02 | 1.04 | 10.12 | 0.4348 | 37.40 | -13.45 | 6.03 | -19.38 | 9.18 | 12.47 | 11.84 |
Akzo Nobel NV | 79.23bn | 4.21bn | 71.14bn | 35.40k | 16.89 | 2.08 | 9.76 | 0.8979 | 3.31 | 3.29 | 61.96 | 26.80 | 0.6991 | 3.57 | 3.75 | 301,733.00 | 4.00 | 4.15 | 6.59 | 6.06 | 40.82 | 40.51 | 5.72 | 6.07 | 0.8947 | 4.71 | 0.5651 | 63.75 | -1.64 | 2.88 | 23.48 | 2.25 | 12.32 | 1.41 |
Symrise AG | 36.42bn | 2.93bn | 107.66bn | 12.54k | 36.80 | 3.84 | 20.45 | 2.96 | 2.81 | 2.81 | 34.92 | 26.90 | 0.6186 | 2.40 | 4.94 | 392,584.40 | 5.02 | 4.99 | 5.80 | 5.95 | 37.10 | 37.93 | 8.11 | 8.13 | 1.64 | 7.17 | 0.401 | 43.83 | 2.42 | 8.44 | 21.59 | 4.04 | 3.44 | 4.10 |
Ems Chemie Holding AG | 16.74bn | 3.70bn | 118.00bn | 2.77k | 31.93 | 7.38 | 28.51 | 7.05 | 19.75 | 19.75 | 89.46 | 85.44 | 0.8586 | -- | 6.07 | 764,838.10 | 19.13 | 22.72 | 22.11 | 27.29 | -- | 45.02 | 22.28 | 23.25 | 3.72 | 245.25 | 0.0153 | 87.87 | -10.36 | -1.14 | -14.01 | -2.51 | -3.87 | 1.57 |
Novozymes A/S | 22.73bn | 2.11bn | 168.03bn | 10.45k | 58.52 | 2.29 | 35.58 | 7.39 | 6.93 | 6.93 | 67.34 | 176.63 | 0.32 | 2.66 | 5.05 | 3,552,654.00 | 2.96 | 13.46 | 3.43 | 17.84 | 46.67 | 55.56 | 9.25 | 20.12 | 0.687 | 12.09 | 0.1531 | 38.89 | 1.82 | 4.47 | -17.86 | -1.28 | 8.12 | 4.41 |
Data as of Nov 21 2024. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 06 Nov 2024 | 11.90m | 2.87% |
Norges Bank Investment Managementas of 30 Jun 2024 | 10.42m | 2.51% |
APG Asset Management NVas of 31 Dec 2023 | 7.59m | 1.83% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 6.42m | 1.55% |
Impax Asset Management Ltd.as of 31 Oct 2024 | 4.82m | 1.16% |
GuardCap Asset Management Ltd.as of 30 Sep 2024 | 4.54m | 1.10% |
Geode Capital Management LLCas of 14 Nov 2024 | 4.24m | 1.02% |
Handelsbanken Fonder ABas of 31 Oct 2024 | 4.04m | 0.97% |
Eleva Capital SASas of 30 Jun 2024 | 3.54m | 0.85% |
Pictet Asset Management SAas of 31 Oct 2024 | 3.21m | 0.77% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.